- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Soin Neuroscience and Lilac Biosciences Launch Collaboration to Study RNA Signatures in Pain and Neuromodulation
The partnership aims to define reproducible biological markers of pain and neuromodulation response.
Published on Feb. 13, 2026
Got story updates? Submit your updates here. ›
Lilac Biosciences, a biotechnology company spun out of Brown University, and Soin Neuroscience, a developer of neuromodulation technologies for chronic pain, have announced a research collaboration to investigate whether changes in RNA expression can serve as biological correlates of pain states and neuromodulation response.
Why it matters
This collaboration addresses a critical gap in pain research, where most evaluations rely on subjective self-reporting rather than molecular measurements. Defining reproducible RNA changes linked to neuromodulation could advance how pain is evaluated, guide next-generation neuromodulation design, and provide independent validation of spinal cord stimulation efficacy.
The details
The initial phase will use preclinical neuromodulation models to assess RNA profiles under defined spinal cord stimulation parameters, waveforms, and time courses. Lilac will perform RNA profiling and data validation using its quantitative RNA workflows. The partnership may extend to additional pain research programs, including studies of pharmacologic interventions.
- The collaboration was announced on February 13, 2026.
- A joint scientific review on RNA mechanisms in pain biology is planned for later this year.
The players
Lilac Biosciences
A biotechnology company spun out of the Giuliani RNA Center at Brown University, developing quantitative RNA-based analytical tools.
Soin Neuroscience
A developer of neuromodulation technologies for chronic pain, founded by Dr. Amol Soin, a specialist in interventional pain management and spinal cord stimulation.
Dr. Amol Soin
The founder of Soin Neuroscience and a specialist in interventional pain management and spinal cord stimulation.
What they’re saying
“Pain is experienced subjectively but driven by molecular events. Defining reproducible RNA changes linked to neuromodulation could advance how we evaluate pain, guide next-generation neuromodulation design, and use objective endpoints that should provide independent validation of spinal cord stimulation efficacy while limiting bias or subjective endpoint manipulation in future human studies.”
— Dr. Amol Soin, Founder, Soin Neuroscience
“This partnership aligns directly with Lilac's mission to translate next-generation RNA-based technology into applied research settings. Collaborating with Dr. Soin enables the application of quantitative RNA technology in neuromodulation research where objective biological context remains limited.”
— Lilac Biosciences Vice President of Business and Commercial Development
What’s next
The partnership may extend to additional pain research programs, including studies of pharmacologic interventions. A joint scientific review on RNA mechanisms in pain biology is planned for later this year.
The takeaway
This collaboration aims to define reproducible biological markers of pain and neuromodulation response, which could advance how pain is evaluated, guide next-generation neuromodulation design, and provide independent validation of spinal cord stimulation efficacy.
